Cargando…
Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
BACKGROUND: The inhibitory CTLA-4 molecule is a crucial regulator of immune responses and a target for therapeutic intervention in both autoimmunity and cancer. In particular, CTLA-4 is important in controlling antigen-specific immunity, including responses to autoantigens associated with autoimmune...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973056/ https://www.ncbi.nlm.nih.gov/pubmed/27487771 http://dx.doi.org/10.1186/s13075-016-1075-1 |
_version_ | 1782446342884294656 |
---|---|
author | Dahal, Lekh N. Basu, Neil Youssef, Hazem Khanolkar, Rahul C. Barker, Robert N. Erwig, Lars P. Ward, Frank J. |
author_facet | Dahal, Lekh N. Basu, Neil Youssef, Hazem Khanolkar, Rahul C. Barker, Robert N. Erwig, Lars P. Ward, Frank J. |
author_sort | Dahal, Lekh N. |
collection | PubMed |
description | BACKGROUND: The inhibitory CTLA-4 molecule is a crucial regulator of immune responses and a target for therapeutic intervention in both autoimmunity and cancer. In particular, CTLA-4 is important in controlling antigen-specific immunity, including responses to autoantigens associated with autoimmune disease. Here, we investigate cytokine responses to a range of lupus-associated autoantigens and assess whether the alternatively spliced isoform of CTLA-4, soluble CTLA-4 (sCTLA-4), contributes to immune regulation of autoantigen-specific immunity in systemic lupus erythematosus (SLE). METHODS: The cell culture supernatant production of sCTLA-4 as well as the cytokines IL-10, IFN-γ, and IL-17 from peripheral blood mononuclear cells (PBMC) from lupus patients and age- and sex-matched healthy volunteer donors were measured in response to previously identified histone and small nuclear ribonucleoprotein (snRNP) autoantigen-derived peptides (H3(91-105), H4(71-93), and U170K(131-151)) by ELISA. We also examined the functional contribution of sCTLA-4 to immune regulation in the context of these autoantigenic peptides following blockade of sCTLA-4 with a selective anti-sCTLA-4 monoclonal antibody, JMW-3B3. RESULTS: We identified responses to autoantigenic peptides, which revealed qualitative differences in cytokine (IL-10, IL-17, and IFN-γ) profiles between SLE patients and healthy donors. PBMC from healthy donors responded to each of the lupus peptides by secreting IFN-γ and IL-17, but PBMC from SLE patients produced IL-10. Although we did not observe differences in the levels of serum or PBMC culture supernatant sCTLA-4 in either cohort, blockade of sCTLA-4 in PBMC cultures responding to antigen enhanced the cytokine profiles associated with each group. CONCLUSION: The results show that lupus autoantigen-derived peptides display varied immunogenicity in lupus versus healthy volunteer donors, while sCTLA-4 acts to regulate the T-cell activity independently of response profile. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1075-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4973056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49730562016-08-05 Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus Dahal, Lekh N. Basu, Neil Youssef, Hazem Khanolkar, Rahul C. Barker, Robert N. Erwig, Lars P. Ward, Frank J. Arthritis Res Ther Research Article BACKGROUND: The inhibitory CTLA-4 molecule is a crucial regulator of immune responses and a target for therapeutic intervention in both autoimmunity and cancer. In particular, CTLA-4 is important in controlling antigen-specific immunity, including responses to autoantigens associated with autoimmune disease. Here, we investigate cytokine responses to a range of lupus-associated autoantigens and assess whether the alternatively spliced isoform of CTLA-4, soluble CTLA-4 (sCTLA-4), contributes to immune regulation of autoantigen-specific immunity in systemic lupus erythematosus (SLE). METHODS: The cell culture supernatant production of sCTLA-4 as well as the cytokines IL-10, IFN-γ, and IL-17 from peripheral blood mononuclear cells (PBMC) from lupus patients and age- and sex-matched healthy volunteer donors were measured in response to previously identified histone and small nuclear ribonucleoprotein (snRNP) autoantigen-derived peptides (H3(91-105), H4(71-93), and U170K(131-151)) by ELISA. We also examined the functional contribution of sCTLA-4 to immune regulation in the context of these autoantigenic peptides following blockade of sCTLA-4 with a selective anti-sCTLA-4 monoclonal antibody, JMW-3B3. RESULTS: We identified responses to autoantigenic peptides, which revealed qualitative differences in cytokine (IL-10, IL-17, and IFN-γ) profiles between SLE patients and healthy donors. PBMC from healthy donors responded to each of the lupus peptides by secreting IFN-γ and IL-17, but PBMC from SLE patients produced IL-10. Although we did not observe differences in the levels of serum or PBMC culture supernatant sCTLA-4 in either cohort, blockade of sCTLA-4 in PBMC cultures responding to antigen enhanced the cytokine profiles associated with each group. CONCLUSION: The results show that lupus autoantigen-derived peptides display varied immunogenicity in lupus versus healthy volunteer donors, while sCTLA-4 acts to regulate the T-cell activity independently of response profile. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-016-1075-1) contains supplementary material, which is available to authorized users. BioMed Central 2016-08-04 2016 /pmc/articles/PMC4973056/ /pubmed/27487771 http://dx.doi.org/10.1186/s13075-016-1075-1 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Dahal, Lekh N. Basu, Neil Youssef, Hazem Khanolkar, Rahul C. Barker, Robert N. Erwig, Lars P. Ward, Frank J. Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus |
title | Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus |
title_full | Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus |
title_fullStr | Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus |
title_full_unstemmed | Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus |
title_short | Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus |
title_sort | immunoregulatory soluble ctla-4 modifies effector t-cell responses in systemic lupus erythematosus |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973056/ https://www.ncbi.nlm.nih.gov/pubmed/27487771 http://dx.doi.org/10.1186/s13075-016-1075-1 |
work_keys_str_mv | AT dahallekhn immunoregulatorysolublectla4modifieseffectortcellresponsesinsystemiclupuserythematosus AT basuneil immunoregulatorysolublectla4modifieseffectortcellresponsesinsystemiclupuserythematosus AT youssefhazem immunoregulatorysolublectla4modifieseffectortcellresponsesinsystemiclupuserythematosus AT khanolkarrahulc immunoregulatorysolublectla4modifieseffectortcellresponsesinsystemiclupuserythematosus AT barkerrobertn immunoregulatorysolublectla4modifieseffectortcellresponsesinsystemiclupuserythematosus AT erwiglarsp immunoregulatorysolublectla4modifieseffectortcellresponsesinsystemiclupuserythematosus AT wardfrankj immunoregulatorysolublectla4modifieseffectortcellresponsesinsystemiclupuserythematosus |